

Dear INSERT NAME:

Today I am pleased to inform you that the U.S. Food and Drug Administration has approved Diclegis<sup>®</sup> indicated for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. Diclegis will be available within weeks to help your patients control their NVP symptoms throughout the day.

Millions of pregnant women could benefit from an approved NVP treatment<sup>1,2</sup> and Diclegis represents a much needed FDA-approved treatment option. Significantly, the FDA granted Diclegis Pregnancy Category A status.

Duchesnay USA is devoted to safeguarding the health and well-being of pregnant women and their unborn babies. Duchesnay USA appreciates the time that you spent with us discussing NVP and issues related to NVP that are important to you and your patients.

We expect Diclegis to be commercially available in late-May. In the meantime, please let me know if you have any questions.

Sincerely,

[NAME]

---

<sup>1</sup> Martin JA, Hamilton BE, Ventura SJ, et al. Births: Final data for 2009. Centers for Disease Control National Vital Statistics Report. 2011;60(1).

<sup>2</sup> American College of Obstetricians and Gynecologists. Nausea and vomiting of pregnancy. ACOG Practice Bulletin. 2004;52.